Theravance Biopharma
TBPH
84 hedge funds and large institutions have $1.31B invested in Theravance Biopharma in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 11 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 25
0% more funds holding
Funds holding: 84 → 84 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
1.2% less ownership
Funds ownership: 87.94% → 86.74% (-1.2%)
19% less capital invested
Capital invested by funds: $1.62B → $1.31B (-$312M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
100% less call options, than puts
Call options by funds: $2K | Put options by funds: $944K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.12M |
| 2 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$1.92M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.45M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.44M |
| 5 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$6.16M |
| 2 |
First Manhattan
New York
|
-$4.71M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.72M |
| 4 |
BlackRock
New York
|
-$1.81M |
| 5 |
Goldman Sachs
New York
|
-$1.75M |
TBPH Hedge Fund Activity: Q4 2017 in Review
84 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2017, worth a combined $1.31B — down 19% from $1.62B a quarter earlier.
Fund positioning in TBPH was balanced in Q4 2017: 11 funds opened new positions, 11 closed out, 30 added to existing stakes and 25 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.12M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.16M sold.
- 84 institutional investors held Theravance Biopharma (TBPH) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $1.31B of Theravance Biopharma stock for Q4 2017, down 19% quarter-over-quarter.
- 11 funds opened new Theravance Biopharma positions in Q4 2017 and 11 closed out, a net change of 0 holders.
- The largest Theravance Biopharma buyer in Q4 2017 was Vanguard Group, an estimated $3.12M added.
- The largest Theravance Biopharma seller in Q4 2017 was Opaleye Management, an estimated $6.16M sold.
Based on aggregated 13F filings for Q4 2017.